Patient-Derived iPSC Lines to Model Major Depressive Disorder and Bipolar Disorder: Insights from a Mother–Child Dyad

Study Background and Research Question

Major depressive disorder (MDD) and bipolar disorder (BD) are among the most prevalent and heritable psychiatric illnesses, yet their underlying molecular mechanisms remain incompletely understood. Genome-wide association studies have revealed considerable genetic overlap between these disorders, but also point to distinct pathophysiological pathways. Traditional models have been limited in their ability to disentangle shared versus unique disease mechanisms, especially on a controlled genetic background. Addressing this gap, the reference study reports the derivation of two human induced pluripotent stem cell (iPSC) lines from a mother–child pair—one diagnosed with MDD and the other with BD—providing a unique platform for comparative analysis of these disorders in a genetically related context.

Key Innovation from the Reference Study

The principal innovation of this work lies in the generation and comprehensive validation of iPSC lines (HZSMHCI001-A and HZSMHCI004-A) from a mother–child dyad afflicted with distinct mood disorders. Unlike previous efforts that typically use unrelated donors or focus on a single diagnosis, this approach preserves genetic relatedness while capturing disease-specific phenotypes. The resulting cell lines enable researchers to control for background genetic variation, thereby isolating molecular and cellular differences attributable to MDD versus BD. This resource, archived in public stem cell registries, opens avenues for personalized disease modeling and therapeutic screening in psychiatric research.

Methods and Experimental Design Insights

Peripheral blood mononuclear cells (PBMCs) were obtained from a 34-year-old male with BD and his 57-year-old mother diagnosed with MDD, both of Han Chinese ethnicity. Reprogramming was performed using a non-integrating episomal plasmid system encoding OCT4, SOX2, NANOG, LIN28, c-MYC, KLF4, and SV40LT. This method avoids genomic integration, reducing the risk of insertional mutagenesis and enhancing safety for downstream applications.

Quality control measures included:

• Verification of transgene clearance by quantitative PCR (<0.1 copy per cell).
• Karyotype analysis by G-banding to confirm genomic stability (46XX and 46XY, resolution 450–500).
• Immunocytochemistry and flow cytometry for pluripotency markers (Oct4, TRA-1-60, SSEA-4, TRA-1-81).
• Teratoma formation assays to establish trilineage differentiation capacity in vivo.
• Short tandem repeat (STR) profiling at 23 loci for cell line authentication.
• Extensive mycoplasma and viral screening.

All protocols were approved by the Hangzhou Seventh People's Hospital Ethics Committee and cell lines were archived in recognized repositories (HZSMHCI001-A, HZSMHCI004-A).

Core Findings and Why They Matter

Both iPSC lines exhibited typical pluripotent morphology and robust expression of canonical markers, as confirmed by flow cytometry and immunocytochemistry. Karyotype analysis demonstrated chromosomal integrity, while teratoma assays provided evidence of differentiation into ectodermal, mesodermal, and endodermal derivatives. Importantly, genomic PCR confirmed successful removal of episomal reprogramming vectors, a critical step for accurate disease modeling.

The unique resource value arises from the familial context: parallel iPSC lines from genetically related individuals with divergent psychiatric phenotypes allow direct comparison of cell-intrinsic disease mechanisms. This is crucial for parsing the molecular correlates of MDD and BD, supporting the development of more precise therapeutic interventions and biomarker discovery. The iPSC lines also facilitate the generation of patient-specific neuronal cultures, further enabling mechanistic studies relevant to neuropsychiatric disorders.

Comparison with Existing Internal Articles

Several internal reviews have addressed the strategic use of ROCK inhibitors, like Y-27632 dihydrochloride, in stem cell research and disease modeling. For example, one analysis emphasizes the importance of modulating Rho/ROCK signaling for neuro-epithelial co-culture systems and advanced organoid platforms. Another review discusses how selective ROCK1/2 inhibition enhances stem cell viability and reproducibility, which is especially relevant when culturing sensitive lines such as patient-derived iPSCs. The current reference study does not explicitly report the use of ROCK inhibitors in reprogramming or maintenance, but the described protocols and characterization steps are compatible with established workflows that leverage such molecules for stem cell viability enhancement and inhibition of Rho-mediated stress fiber formation.

This alignment underscores the translational potential of integrating selective ROCK inhibitors into protocols involving disease-specific iPSC lines, especially where cell survival and maintenance are critical—an approach highlighted in the broader stem cell and cancer research literature.

Limitations and Transferability

While these iPSC lines provide a valuable disease modeling platform, some limitations should be acknowledged. First, the sample size—two individuals—limits generalizability and does not capture the full genetic or phenotypic spectrum of MDD or BD. Second, the study does not include functional analyses of differentiated derivatives (e.g., electrophysiological profiling of neurons), which are critical for linking genotype to phenotype. Lastly, while non-integrating episomal reprogramming is considered safer than viral methods, rare genomic alterations cannot be entirely excluded.

Nevertheless, the resource's transferability is high for researchers aiming to dissect disease-specific cellular phenotypes on a controlled genetic background, particularly in psychiatric and neurodevelopmental research domains.

Protocol Parameters

• Donor selection: Genetically related individuals with distinct clinical diagnoses (e.g., MDD and BD) to facilitate controlled comparisons.
• Cell source: Peripheral blood mononuclear cells (PBMCs) for minimally invasive sampling.
• Reprogramming method: Non-integrating episomal plasmids expressing key pluripotency factors (OCT4, SOX2, NANOG, LIN28, c-MYC, KLF4, SV40LT).
• Pluripotency validation: Immunocytochemistry and flow cytometry for Oct4, TRA-1-60, SSEA-4, and TRA-1-81; teratoma assay for trilineage differentiation.
• Genomic stability: Karyotype analysis (G-banding) at 450–500 band resolution; STR profiling for line authentication.
• Transgene clearance: Quantitative PCR to confirm the absence of residual reprogramming vectors.
• Contamination screening: PCR-based mycoplasma and viral testing before downstream differentiation.
• Recommended support reagents: For optimal cell survival during passaging or single-cell cloning, incorporate a selective ROCK inhibitor (e.g., Y-27632 dihydrochloride) as established in related workflows.

Research Support Resources

For researchers working with patient-derived iPSC lines—especially those modeling neuropsychiatric disorders—ensuring high cell viability and reproducibility is essential. A selective ROCK inhibitor such as Y-27632 dihydrochloride (SKU A3008, APExBIO) is widely used to enhance stem cell survival, support efficient passaging, and inhibit Rho-mediated stress fiber formation during critical steps of iPSC culture and expansion. Protocols described in both the reference study and internal reviews can be adapted with the inclusion of this compound, facilitating robust and reproducible disease modeling workflows.